Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
Date:7/9/2008

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis and other related conditions.

The Phase 1b trial was a randomized, double-blind, placebo-controlled, multiple-ascending dose trial in 50 healthy adult male and female volunteers. Daily doses ranged from 15 mg to 240 mg and were generally well tolerated. The most frequently reported adverse event was headache, which was more common in the placebo group than in any APD791 dose group. None of the adverse events occurred in a dose-related fashion with the exception of epistaxis (nose bleed), which occurred in two volunteers in the 240 mg group, a dose outside the anticipated therapeutic range.

In addition to evaluating APD791's safety and tolerability profile, the trial evaluated the pharmacokinetics and pharmacodynamics of multiple oral doses of APD791 over a period of one week. APD791 was rapidly absorbed and exposures were related to dose. Dose-dependent inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 15 mg dose and will permit the identification of exposure ranges that produce minimal, moderate and near-complete inhibition of serotonin-mediated platelet aggregation. These results further support APD791's novel mechanism of action and preclinical and Phase 1a clinical trial data.

"These results support APD791's potential to treat a variety of central and peripheral conditions related to arterial thromb
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
3. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
6. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
7. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Isis Pharmaceuticals Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Reported at American Association for Cancer Research ... -- Favrille,Inc. , a biopharmaceutical company developing ... announced,results from a new study showing enhanced ... key component in the Company's,Id/KLH immunotherapy product ...
... Origin May Be Useful in Cancer Treatment,Decisions , ... Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today ... might be used to,determine the original location of ... the annual meeting of the American Association,for Cancer ...
Cached Medicine Technology:Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 2Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 3Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 4Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... teenagers have a lot in common: Sugary soda. Fast-food ... Low-income teenagers are almost three times more likely to ... to new research from the UCLA Center for Health ... 21 percent of teenagers living in low-income families are ...
... Calif., Dec. 10 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... (POC) products under the,Vantus brand. Unveiling of the ... 54th Annual Convention of the American Association of Equine,Practitioners ...
... HONOLULU, Dec. 10 Hoana Medical announced today that ... at the Institute for Healthcare Improvement (IHI) premier event ... leaders in hospital,safety. , ... conjunction with the,IHI event, to introduce its LifeGurney system, ...
... prostate cancer patients with drugs that block hormonal activity ... from cardiovascular disease, according to a study led by ... report from members of the same study team found ... risk of diabetes and heart disease, the current study ...
... A group of nutritionists from Extenso, the Universit de ... chefs from the Institut de tourisme et d,htellerie du ... and early childhood centres. The goal is to help ... for kids. , The nutrition team will provide its ...
... Ga., Dec. 10 Joe Jurevicius, Tom Brady, ... few months the list,of top professional football players ... read as a who,s who of the National ... infections is healthcare facilities,where athletes are undergoing surgeries, ...
Cached Medicine News:Health News:Obesity among state's low-income teens nearly triple that of more affluent peers 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 3Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 4Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 2Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 3Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 4Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 2Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 3Health News:New partnership to foster healthier food habits in early childhood 2Health News:Staph Infections Hit Professional Football Hard 2Health News:Staph Infections Hit Professional Football Hard 3
Pocket-sized instrument with direct illumination. Avaliable in black, green or blue....
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
... delivers power and reliability with proprietary ... Diode side-pumping technology drives 2.5 W ... Spectra system, and active resonator temperature ... system reliability from your first treatment ...
Medicine Products: